HICKSVILLE, NY, April 06, 2018 -- Canbiola, Inc. (OTC PINK: CANB) in its continuing effort to educate the public on the benefits of CBD and expand its market share, Dr. Kornfeld, Canbiola’s Medical Advisor, will be featured on the “Live It Up! with Donna Drake” TV talk show, this Saturday morning, April 7, 2018 at 6:30 AM EST on Local WLNY, Spectrum – Channel 10 and Optimum – Channel 10, FIOS 10, check other listings.
“Live It Up with Donna Drake!”, a Drake Media Network production, is a weekly television show, airing in the tri-state area of New York, New Jersey, and Connecticut. This action-packed show features inspirational stories and guests who provide helpful information and resources and is filled with positive messages of hope and motivation to empower both men and women. “We feature celebs, business owners and non-profits who provide resources and tips to help our community thrive!” explains Donna Drake, executive producer, founder, and co-host of the show. Donna Drake is an international award-winning creative artist, writer, producer, and actress. She created "Live It Up!" to share positive messages of hope that inspire and empower those who need it most.
Marco Alfonsi, Canbiola CEO, stated, “We are excited to be reaching out to over 8 million viewers throughout the tri-state area; this event will allow us to better educate the public on the benefits of our products.”
Dr. Kornfeld stated, "It's very important to me to join forces with a company that produces and distributes only the highest quality products with the patient in mind. Canbiola is just that company. They offer numerous CBD products in pure and different forms that answer the needs of the public. As a doctor, I am committed to helping my patients avoid potentially harmful drugs and to help them heal naturally. Canbiola's CBD products have many applications in medicine and will surely help many of my patients."
Dr. Robert A. Kornfeld, the first holistic oriented podiatrist in the U.S., has been practicing integrative and functional medicine for chronic foot and ankle pain for over 35 years. Dr. Kornfeld has developed protocols for all foot and ankle pathology that assist the body in achieving improved health while he eliminates the chronic pain syndrome. Dr. Kornfeld is an expert in homeopathic injection therapy, prolotherapy, platelet-rich-plasma injections, amniotic fluid injections, nutritional and herbal medicine, lower extremity biomechanics, and functional medicine.
The Chronic Foot Pain Center specializes in patients with chronic foot and ankle pain who have been failed by traditional medicine and surgery, as well as those patients seeking a more natural approach to their health care.
Dr. Kornfeld is Board Certified in Integrative Medicine by the American Association of Integrative Medicine and is a Diplomate of the College of Physicians, AAIM.
Dr. Kornfeld has lectured extensively throughout the country, has hosted his own radio shows in NYC, has been featured on local TV shows and is the Founder of The Institute for Integrative Podiatric Medicine. He is a former Assistant Professor - New York College of Podiatric Medicine - Dept. of Integrative Medicine.
CERTIFICATIONS:
- Fellow - American College of Alternative Medicine
- Board Certified - American Association of Integrative Medicine
- Diplomate-College of Physicians - American Association of Integrative Medicine
- Diplomate - American Board of Alternative Medicine
- Diplomate - American Alternative Medical Association
- Board Certified - International Society of Homotoxicology
APPOINTMENTS:
- Director - Post-Graduate Preceptorship in Podiatric Medicine and Surgery at Mt. Hope Medical Center - Bronx, N.Y. 1982-1987
- Director - Holistic & Complementary Podiatric Medicine, LLC - 1997 – present
- Former Adjunct Assistant Professor – New York College of Podiatric Medicine - Dept. of Integrative Medicine
- Founder - Institute for Integrative Podiatric Medicine – 2008
About Canbiola, Inc.
Canbiola, Inc. is a public company trading under symbol CANB.
Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola is in the process of developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states. The company has already launched several products found at www.canbiola.com.
The company also owns two technological solutions, WRAPmail (US Patent 8,572,275), which turns traditional email into a powerful marketing and branding tool, as well Prosperity Systems and the Bullseye platform of document management and compliance targeted at broker-dealers, public companies, and governmental agencies providing a flawless all-in-one solution for document management, retention and compliance.
Forward-looking statements and risks and uncertainties Matters discussed in this press release contain forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.
CONTACT INFORMATION
Canbiola Investor Relations
Email: [email protected]
Phone: (516) 595-9544
website: http://www.canbiola.com
Follow us on Twitter and Facebook


Apple Restores Telegram to App Store After Content Policy Violation
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
Capital One Says AML Review Led to Closure of Trump Organization Accounts
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 



